Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized , Open Label, Three Arm, Parallel Group, Single Dose, Comparative Pharmacokinetic , Safety, and Immunogenicity Study Comparing KSHB002 (Abatacept) 125 mg/ ml Pre-filled Injection With US-Licenced ORENCIA and EU-Approved ORENCIA Administered Through Subcutaneous Route in Healthy Adult Human Volunteers

NCT06929039 is registered in ClinicalTrials.gov with Kashiv BioSciences, LLC as lead sponsor.

NCT NCT06929039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06929039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized , Open Label, Three Arm, Parallel Group, Single Dose, Comparative Pharmacokinetic , Safety, and Immunogenicity Study Comparing KSHB002 (Abatacept) 125 mg/ ml Pre-filled Injection With US-Licenced ORENCIA and EU-Approved ORENCIA Administered Through Subcutaneous Route in Healthy Adult Human Volunteers
Lead sponsor
Kashiv BioSciences, LLC
Phase
Phase 1
Overall status
Completed
Start date
July 4, 2024
Completion date
February 25, 2025
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra